Pashtoon Kasi, MD
Medical Oncology · Irvine, CANPI 1215167648
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,648 of the $82,115 with a category attached, or 83.6%. 23 manufacturers reported payments, led by Merck at 31.4% of the total. Reporting peaked in 2021 at $29,802 and has fallen 99.6% since, to $122 in 2025.
Across 65 payments — averaging $1263.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$26K
- Regeneron$14K
- Seagen Inc.$8K
- Lilly USA, LLC$6K
- Eisai Inc.$5K
- Bayer$4K
- plus $20K from 17 others
Across 141 payments — averaging $21,664 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$827K
- Novartis$778K
- Tersera Therapeutics LLC$442K
- Amgen$218K
- Clovis Oncology, Inc.$217K
- AstraZeneca$200K
- plus $373K from 7 others
What the payments were for
- Consulting fees$68,64884%
- Speaking & faculty fees$9,22011%
- Travel & lodging$2,5433%
- Food & beverage$1,6162%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $25,810 |
| Regeneron | 5 | $13,583 |
| Seagen Inc. | 9 | $7,656 |
| Lilly USA, LLC | 1 | $6,300 |
| Eisai Inc. | 3 | $4,684 |
| Bayer | 3 | $4,313 |
| AstraZeneca | 13 | $3,655 |
| Illumina, Inc. | 1 | $3,120 |
| Incyte Corporation | 2 | $2,792 |
| Daiichi Sankyo Inc. | 2 | $2,775 |
| Beigene USA, Inc. | 2 | $2,357 |
| Servier Pharmaceuticals LLC | 1 | $2,240 |
| Taiho Oncology, Inc. | 1 | $1,980 |
| Menarini Silicon Biosystems, Inc. | 2 | $209 |
| Biontech SE | 1 | $166 |
| Genentech USA, Inc. | 1 | $127 |
| Novartis | 3 | $86 |
| Amgen | 1 | $80 |
| GSK | 1 | $67 |
| Ipsen Biopharmaceuticals, Inc | 2 | $51 |
| Tempus AI, Inc | 1 | $27 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,115 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 21 | $308 |
| Prochlorperazine Maleate | 14 | $175 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Irvine
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.